Skip to main content
Top
Published in: Clinical Drug Investigation 7/2008

01-07-2008 | Original Research Article

Variability in the Diagnosis and Management of Patients with Alzheimer’s Disease and Cerebrovascular Disease

Results from the GALATEA Multicentre, Observational Study

Authors: Pedro Gil, Dr José Luis Dobato Ayuso, José Manuel Marey, Manuel Antón, Carlos Guzmán Quilo

Published in: Clinical Drug Investigation | Issue 7/2008

Login to get access

Abstract

Background and objectives:

There is frequently a degree of variability among different types of dementia specialists in clinical practice in both the clinical diagnosis and the management of patients with Alzheimer’s disease and cerebrovascular disease (CVD). This variability may have an adverse effect on the use of medical resources as well as on patients’ well-being. The main objective of this study was to describe the current diagnosis and management of patients with Alzheimer’s disease and CVD in Spain. Other objectives were to determine whether there were significant differences in the diagnosis and management of these patients depending on physician characteristics and/or patient profile.

Methods:

This was an epidemiological, cross-sectional, multicentre study in which 107 physicians participated and recruited patients with Alzheimer’s disease and CVD. During a 1-month period, physicians collected data on diagnosis, treatment, follow-up, adverse events and other characteristics of these patients. This study was performed under naturalistic conditions, and no restrictions were imposed on the physicians.

Results:

Physicians were mainly neurologists (76%), geriatricians (14%) and psychiatrists (8%) with a median age of 42 years. A total of 720 patients with a diagnosis of Alzheimer’s disease and CVD were recruited. The median age of the patients was 78 years. Almost all patients were diagnosed by neuroimaging (98%) together with medical history (87%). The existence of a previous stroke coincident with cognitive deterioration was used as a diagnostic method in only 27% of patients. Among non-pharmacological treatment measures, diet was the most frequently recommended (61%), followed by cognitive stimulation (50%) and physical exercise (44%). The most commonly used pharmacological treatments were galantamine (59%), donepezil (14%) and rivastigmine (11%). The incidence of adverse events was low (3%), and all were considered non-severe. There were no significant correlations between physician age or physician years of practice and the diagnostic method used. The diagnostic method most frequently used by psychiatrists (100%) and geriatricians (97%) was medical history whereas this method was not used as much by neurologists (85%) [p = 0.0150]. Neuroimaging methods were more frequently used by neurologists (99%) and geriatricians (96%) compared with psychiatrists (84%) [p < 0.0001]. Patients with attention disorders had a higher frequency of follow-up visits (p = 0.0145) and were treated less frequently with donepezil (p = 0.0118).

Conclusions:

Several possible areas of improvement in the management of patients with Alzheimer’s disease and CVD were identified. These included better control of cardiovascular risk factors, such as hypertension and hyperlipidaemia, which have a high prevalence in this population, as has been shown in the present study. These potentially modifiable risk factors may assist in the prevention of Alzheimer’s disease. Also identified was the need to emphasize the role of general practitioners in decreasing the time to diagnosis of Alzheimer’s disease. Development of well designed clinical practice guidelines may help physicians decide on the most appropriate ways of diagnosing and managing patients with Alzheimer’s disease and CVD and reduce practice variations between different medical specialities.
Literature
1.
go back to reference Klafki HW, Staufenbiel M, Kornhuber J, et al. Therapeutic approaches to Alzheimer’s disease. Brain 2006 Nov; 129 (Pt 11): 2840–55PubMedCrossRef Klafki HW, Staufenbiel M, Kornhuber J, et al. Therapeutic approaches to Alzheimer’s disease. Brain 2006 Nov; 129 (Pt 11): 2840–55PubMedCrossRef
2.
go back to reference Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke 2004; 35 (11 Suppl. 1): 2620–2PubMedCrossRef Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke 2004; 35 (11 Suppl. 1): 2620–2PubMedCrossRef
3.
go back to reference Munoz DG, Feldman H. Causes of Alzheimer’s disease. CMAJ 2000; 162(1): 65–72PubMed Munoz DG, Feldman H. Causes of Alzheimer’s disease. CMAJ 2000; 162(1): 65–72PubMed
5.
go back to reference Tyas SL, Manfreda J, Strain LA, et al. Risk factors for Alzheimer’s disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol 2001; 30(3): 590–7PubMedCrossRef Tyas SL, Manfreda J, Strain LA, et al. Risk factors for Alzheimer’s disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol 2001; 30(3): 590–7PubMedCrossRef
6.
go back to reference Kerr ML, Small DH. Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer’s disease: function, regulation of proteolysis, and implications for drug development. J Neurosci Res 2005; 80(2): 151–9PubMedCrossRef Kerr ML, Small DH. Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer’s disease: function, regulation of proteolysis, and implications for drug development. J Neurosci Res 2005; 80(2): 151–9PubMedCrossRef
7.
go back to reference Wang B, Jin F, Yang Z, et al. The insertion polymorphism in angiotensin-converting enzyme gene associated with the APOE epsilon 4 allele increases the risk of late-onset Alzheimer disease. J Mol Neurosci 2006; 30(3): 267–71PubMedCrossRef Wang B, Jin F, Yang Z, et al. The insertion polymorphism in angiotensin-converting enzyme gene associated with the APOE epsilon 4 allele increases the risk of late-onset Alzheimer disease. J Mol Neurosci 2006; 30(3): 267–71PubMedCrossRef
8.
go back to reference Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 2007; 6(4): 373–8PubMedCrossRef Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 2007; 6(4): 373–8PubMedCrossRef
9.
go back to reference Cacabelos R, Fernandez-Novoa L, Lombardi V, et al. Cerebrovascular risk factors in Alzheimer’s disease: brain hemodynamics and pharmacogenomic implications. Neurol Res 2003; 25(6): 567–80PubMedCrossRef Cacabelos R, Fernandez-Novoa L, Lombardi V, et al. Cerebrovascular risk factors in Alzheimer’s disease: brain hemodynamics and pharmacogenomic implications. Neurol Res 2003; 25(6): 567–80PubMedCrossRef
10.
go back to reference Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16(3): 131–6PubMedCrossRef Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16(3): 131–6PubMedCrossRef
11.
go back to reference Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer’s disease, 2000–2050: potential implication of treatment advances. Ann Rev Public Health 2002; 23: 213–31CrossRef Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer’s disease, 2000–2050: potential implication of treatment advances. Ann Rev Public Health 2002; 23: 213–31CrossRef
12.
go back to reference Haan MN, Wallace R. Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health 2004; 25: 1–24PubMedCrossRef Haan MN, Wallace R. Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health 2004; 25: 1–24PubMedCrossRef
13.
go back to reference Dufouil C, Alperovitch A. Epidemiology of Alzheimer’s disease [in French]. Rev Prat 2005; 55(17): 1869–78PubMed Dufouil C, Alperovitch A. Epidemiology of Alzheimer’s disease [in French]. Rev Prat 2005; 55(17): 1869–78PubMed
14.
go back to reference Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006; 14(7): 561–72PubMedCrossRef Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006; 14(7): 561–72PubMedCrossRef
15.
go back to reference Olazaran J, Muniz R, Reisberg B, et al. Benefits of cognitivemotor intervention in MCI and mild to moderate Alzheimer disease. Neurology 2004; 63(12): 2348–53PubMedCrossRef Olazaran J, Muniz R, Reisberg B, et al. Benefits of cognitivemotor intervention in MCI and mild to moderate Alzheimer disease. Neurology 2004; 63(12): 2348–53PubMedCrossRef
16.
go back to reference Clare L, Woods RT, Moniz Cook ED, et al. Cognitive rehabilitation and cognitive training for early-stage Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev 2003; (4): CD003260 Clare L, Woods RT, Moniz Cook ED, et al. Cognitive rehabilitation and cognitive training for early-stage Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev 2003; (4): CD003260
17.
go back to reference Looi JC, Sachdev PS. Vascular dementia as a frontal subcortical system dysfunction. Psychol Med 2000 Sep; 30(5): 997–1003PubMedCrossRef Looi JC, Sachdev PS. Vascular dementia as a frontal subcortical system dysfunction. Psychol Med 2000 Sep; 30(5): 997–1003PubMedCrossRef
18.
go back to reference Antoine V, Rigaud AS. Alzheimer’s disease: cardiovascular risk factors must be assessed [in French]. Rev Med Interne 2006; 27(1): 21–31PubMedCrossRef Antoine V, Rigaud AS. Alzheimer’s disease: cardiovascular risk factors must be assessed [in French]. Rev Med Interne 2006; 27(1): 21–31PubMedCrossRef
19.
go back to reference Cowppli-Bony P, Dartigues JF, Orgogozo JM. Vascular risk factors and Alzheimer disease risk: epidemiological studies review. Psychol Neuropsychiatr Vieil 2006; 4(1): 47–60PubMed Cowppli-Bony P, Dartigues JF, Orgogozo JM. Vascular risk factors and Alzheimer disease risk: epidemiological studies review. Psychol Neuropsychiatr Vieil 2006; 4(1): 47–60PubMed
20.
go back to reference Rockwood K. Mixed dementia: Alzheimer’s and cerebrovascular disease. Int Psychogeriatr 2003; 15Suppl. 1: 39–46PubMedCrossRef Rockwood K. Mixed dementia: Alzheimer’s and cerebrovascular disease. Int Psychogeriatr 2003; 15Suppl. 1: 39–46PubMedCrossRef
21.
go back to reference Fernando MS, Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol sci 2004; 226(1–2): 13–7PubMedCrossRef Fernando MS, Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol sci 2004; 226(1–2): 13–7PubMedCrossRef
22.
go back to reference Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Methods Find Exp Clin Pharmacol 2007 Jul; 29Suppl. A: 1–91PubMed Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Methods Find Exp Clin Pharmacol 2007 Jul; 29Suppl. A: 1–91PubMed
23.
go back to reference Kalaria RN. Comparison between Alzheimer’s disease and vascular dementia: implications for treatment. Neurol Res 2003; 25(6): 661–4PubMedCrossRef Kalaria RN. Comparison between Alzheimer’s disease and vascular dementia: implications for treatment. Neurol Res 2003; 25(6): 661–4PubMedCrossRef
24.
go back to reference Davis P, Gribben B, Scott A, et al. The ’supply hypothesis’ and medical practice variation in primary care: testing economic and clinical models of inter-practitioner variation. Soc sci Med 2000; 50(3): 407–18PubMedCrossRef Davis P, Gribben B, Scott A, et al. The ’supply hypothesis’ and medical practice variation in primary care: testing economic and clinical models of inter-practitioner variation. Soc sci Med 2000; 50(3): 407–18PubMedCrossRef
25.
go back to reference Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98PubMedCrossRef Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98PubMedCrossRef
26.
go back to reference Whitmer RA, Gunderson EP, Quesenberry Jr CP, et al. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 2007; 4(2): 103–9PubMedCrossRef Whitmer RA, Gunderson EP, Quesenberry Jr CP, et al. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 2007; 4(2): 103–9PubMedCrossRef
27.
go back to reference Luchsinger JA, Reitz C, Honig LS, et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65(4): 545–51PubMedCrossRef Luchsinger JA, Reitz C, Honig LS, et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65(4): 545–51PubMedCrossRef
28.
go back to reference Hayden KM, Zandi PP, Lyketsos CG, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 2006; 20(2): 93–100PubMedCrossRef Hayden KM, Zandi PP, Lyketsos CG, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 2006; 20(2): 93–100PubMedCrossRef
29.
go back to reference Skoog I, Gustafson D. Update on hypertension and Alzheimer’s disease. Neurol Res 2006; 28(6): 605–11PubMedCrossRef Skoog I, Gustafson D. Update on hypertension and Alzheimer’s disease. Neurol Res 2006; 28(6): 605–11PubMedCrossRef
30.
go back to reference Wilkinson D, Stave C, Keohane D, et al. The role of general practitioners in the diagnosis and treatment of Alzheimer’s disease: a multinational survey. J Int Med Res 2004; 32(2): 149–59PubMed Wilkinson D, Stave C, Keohane D, et al. The role of general practitioners in the diagnosis and treatment of Alzheimer’s disease: a multinational survey. J Int Med Res 2004; 32(2): 149–59PubMed
31.
go back to reference Solomon PR, Murphy CA. Should we screen for Alzheimer’s disease? A review of the evidence for and against screening Alzheimer’s disease in primary care practice. Geriatrics 2005; 60(11): 26–31PubMed Solomon PR, Murphy CA. Should we screen for Alzheimer’s disease? A review of the evidence for and against screening Alzheimer’s disease in primary care practice. Geriatrics 2005; 60(11): 26–31PubMed
32.
go back to reference Thomas JM. Early screening of Alzheimer’s disease by the general practitioner: review of the literature. Rev Med Brux 2005; 26(4): S279–88PubMed Thomas JM. Early screening of Alzheimer’s disease by the general practitioner: review of the literature. Rev Med Brux 2005; 26(4): S279–88PubMed
33.
go back to reference Pope SK, Shue VM, Beck C. Will a healthy lifestyle help prevent Alzheimer’s disease? Annu Rev Public Health 2003; 24: 111–32PubMedCrossRef Pope SK, Shue VM, Beck C. Will a healthy lifestyle help prevent Alzheimer’s disease? Annu Rev Public Health 2003; 24: 111–32PubMedCrossRef
34.
go back to reference Polidori MC. Oxidative stress and risk factors for Alzheimer’s disease: clues to prevention and therapy. J Alzheimers Dis 2004; 6(2): 185–91PubMed Polidori MC. Oxidative stress and risk factors for Alzheimer’s disease: clues to prevention and therapy. J Alzheimers Dis 2004; 6(2): 185–91PubMed
35.
go back to reference Grytten J, Sorensen R. Practice variation and physician-specific effects. J Health Econ 2003; 22(3): 403–18PubMedCrossRef Grytten J, Sorensen R. Practice variation and physician-specific effects. J Health Econ 2003; 22(3): 403–18PubMedCrossRef
Metadata
Title
Variability in the Diagnosis and Management of Patients with Alzheimer’s Disease and Cerebrovascular Disease
Results from the GALATEA Multicentre, Observational Study
Authors
Pedro Gil
Dr José Luis Dobato Ayuso
José Manuel Marey
Manuel Antón
Carlos Guzmán Quilo
Publication date
01-07-2008
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 7/2008
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200828070-00004

Other articles of this Issue 7/2008

Clinical Drug Investigation 7/2008 Go to the issue

Correspondence

The Authors’ Reply